Document:

Exhibit 10.3

    

     

    

    INTELLECTUAL PROPERTY SECURITY AGREEMENT 

     

          

    This Intellectual Property Security Agreement (this “Agreement”)

        is made as of December 31, 2014, by and between each of the entities listed on Schedule A attached hereto (each, a “Grantor” and collectively, the “Grantors”) and Rory Riggs, an individual (in his capacity as Seller Representative under the Exchange Agreement referenced below) (“Secured Party”).

     

          

    RECITALS

     

      

    A.          Pursuant to that certain Warrant Transfer and Exchange Agreement of even
        date herewith between Cibus Global, Ltd. (“Cibus”), the Persons and Entities listed as Sellers therein, and Secured Party in its capacity as the Seller Representative
        thereunder, (as such agreement may from time to time be amended, restated, supplemented or otherwise modified, the “Exchange Agreement”), the Sellers have agreed to sell
        Subject Warrants to Cibus in exchange for an interest in certain Subject Revenues of Cibus.  All capitalized terms used herein without definition shall have the meanings ascribed to them in the Exchange Agreement.

     

      

    B.          The purchase and sale of the Subject Warrants under the Exchange Agreement
        is conditioned on, among other things, the grant by each of the Grantors to Secured Party on behalf of the Sellers of a security interest in certain property of the Grantors whether presently existing or hereafter acquired.  To that end, each of
        the Grantors is executing in favor of Secured Party this Agreement, granting a security interest in all Collateral (as defined below).

     

      

    NOW, THEREFORE, THE PARTIES HERETO AGREE AS FOLLOWS:

     

      

    1.          Grant of
            Security Interest.  As collateral security for the prompt and complete payment and performance of all of Cibus’ present or future obligations under the Exchange Agreement, each Grantor hereby grants a security interest and mortgage
        to Secured Party (in its capacity as the Seller Representative), as security, in and to such Grantor’s entire right, title and interest in, to and under the following intellectual property, now owned or hereafter acquired by such Grantor or in
        which such Grantor now holds or hereafter acquires any interest (all of which shall collectively be called the “Collateral” for purposes of this Agreement):

     

      

    (a)          Any and all copyrights, whether registered or unregistered, held pursuant
        to the laws of the United States, any State thereof or of any other country or jurisdiction; all registrations, applications and recordings in the United States Copyright Office or in any similar office or agency of the United States, and State
        thereof or any other country or jurisdiction; all continuations, renewals, or extensions thereof; and any registrations to be issued under any pending applications, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

    
      1

      
        

    

    (b)          All letters patent of, or rights corresponding thereto in, the United
        States or any other country or jurisdiction, all registrations and recordings thereof, and all applications for letters patent of, or rights corresponding thereto in, the United States or any other country or jurisdiction, including, without
        limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country or jurisdiction;  all reissues, continuations,
        continuations-in-part or extensions thereof;  all petty patents, divisionals, and patents of addition; and all patents to be issued under any such applications, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

     

      

    (c)          All trademarks, trade names, corporate names, business names, trade
        styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all
        registrations and recordings thereof, and any applications in connection therewith, including, without limitation, registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the
        United States, any State thereof or any other country or jurisdiction or any political subdivision thereof, and  reissues, extensions or renewals thereof, and the entire goodwill of the business of Grantor connected with and symbolized by such
        trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

     

      

    (d)          trade secrets, including, without limitation, patentable inventions, any
        and all product formulae, manufacturing techniques, product specifications, protocols, processes financial information, computer data and programs, and marketing and business plans, and all rights corresponding to any of the foregoing throughout
        the world (collectively, the “Trade Secrets”);

     

      

    (e)          Any and all claims for damages by way of past, present and future
        infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

     

      

    (f)          All licenses or other rights to use any of the Copyrights, Patents,
        Trademarks or Trade Secrets, and all license fees, income, royalties and payments arising from such use to the extent permitted by such license or rights;

     

      

    (g)          All amendments, renewals and extensions of any of the Copyrights,
        Trademarks or Patents; and

    
      2

      
        

    

    (h)          All cash and non-cash proceeds and products of the foregoing, including
        without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

     

        

    Notwithstanding the foregoing, the term “Collateral” shall not include:  (a) “intent-to-use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in
          commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise, but only to the extent the granting of a security interest in such “intent to use” trademarks would be contrary to applicable law or
          (b) any contract, instrument or chattel paper in which such Grantor has any right, title or interest if and to the extent such contract, instrument or chattel paper includes a provision containing a restriction on assignment such that the
          creation of a security interest in the right, title or interest of such Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such contract, instrument or chattel
          paper to enforce any remedy with respect thereto; provided, however, that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise
          consented to the creation hereunder of a security interest in such contract, instrument or chattel paper, or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-407(a) or 9-408(a) of the Code, as applicable and as then in
          effect in any relevant jurisdiction, or any other applicable law (including any bankruptcy codes or principles of equity); provided further that immediately upon the ineffectiveness, lapse or
          termination of any such provision, the term “Collateral” shall include, and such Grantor shall be deemed to have granted a security interest in, all its rights, title and interests in and to such contract, instrument or chattel paper as if such
          provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect Secured Party’s unconditional continuing
          security interest in and to all rights, title and interests of such Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such contract, instrument or chattel paper and in any such monies and
          other proceeds of such contract, instrument or chattel paper.

    

    

    2.          Representations,

            Warranties and Covenants.  Each Grantor represents, warrants, covenants and agrees for and on behalf of itself on and as of the date hereof as follows:

     

      

    (a)          Such Grantor is now the sole owner of the Collateral, except for Permitted
        Liens;

     

      

    (b)          Such Grantor's chief executive office and the office where the Grantor
        keeps its books and records relating to the Collateral, is located at the address set forth on Schedule A attached hereto.

     

      

    (c)          Upon (i) the delivery to Secured Party of any Collateral consisting of
        instruments or other collateral possession of which is required for perfection, (ii) the filing of proper financing statements on form UCC-1 (or other comparable form) in the appropriate filing offices, (iii) the filing of any notices of a security
        interest in the appropriate filing offices, and (iv) the taking by the Secured Party of any other actions that may be required at law for the purpose of perfecting a security interest in intellectual property,  the Secured Party will obtain a
        valid, enforceable first priority perfected lien and security interest in the Collateral except to the extent of any Permitted Liens permitted hereby or under the Exchange Agreement.

    
      3

      
        

    

    (d)          During the term of this Agreement, such Grantor will not create, incur,
        assume or permit to exist any Lien on any of the Collateral, except for (i) the security interest granted under the Exchange Agreement and this Agreement, (ii) Permitted Licenses to Permitted Licensses in accordance with Section 5.12 of the
        Exchange Agreement, (iii) Permitted Liens and (iv) security interests which are subordinated to the security interests granted by this Agreement and the Exchange Agreement.  Furthermore, during the term of this Agreement, such Grantor will not
        transfer any interest in the Collateral except as set forth in the Exchange Agreement;

     

      

    (e)          To its knowledge, each of the issued Patents are in full force and effect
        and have not elapsed, expired or otherwise terminated.  No Grantor has received any written notice relating to the lapse, expiration or other termination of any of the issued Patents, or alleging that, and such Grantor has not received any written
        legal opinion that alleges that an issued Patent is invalid or unenforceable;

     

      

    (f)          Upon request by Secured Party, such Grantor shall deliver to Secured Party
        within thirty (30) days of the last day of each fiscal quarter, a report signed by such Grantor, in form reasonably acceptable to Secured Party, listing any applications or registrations that such Grantor has made or filed in respect of any
        patents, copyrights or trademarks and the status of any outstanding applications or registrations.  Such Grantor shall promptly advise Secured Party of any material change in the composition of the Collateral, including but not limited to any
        subsequent ownership right of the Grantor in or to any Trademark, Patent or Copyright not specified in this Agreement;

     

      

    (g)          Such Grantor shall, from time to time, execute and file such other
        instruments, and take such further actions as Secured Party may reasonably request from time to time to perfect or continue the perfection of Secured Party’s interest in the Collateral.  Such Grantor shall give Secured Party notice of all such
        applications or registrations; and

     

      

    (h)          Such Grantor shall not enter into any agreement that would materially
        impair or conflict with such Grantor’s obligations hereunder without Secured Party’s prior written consent, which consent shall not be unreasonably withheld or delayed.  Such Grantor shall not permit the inclusion in any material contract to which
        it becomes a party of any provisions that would prevent the creation of a security interest in such Grantor’s rights and interests in any property included within the definition of the Collateral acquired under such contracts.

     

      

    3.          Further
            Assurances; Attorney in Fact.

     

      

    (a)          On a continuing basis, each Grantor will make, execute, acknowledge and
        deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings with the United States Patent and
        Trademark Office and the Register of Copyrights, and take all such action as may reasonably be deemed necessary or advisable, or as reasonably requested by Secured Party, to perfect Secured Party’s security interest in all Copyrights, Patents and
        Trademarks and otherwise to carry out the intent and purposes of this Agreement, or for assuring and confirming to Secured Party the grant or perfection of a security interest in all Collateral.

    
      4

      
        

    

    (b)          Each Grantor hereby irrevocably appoints Secured Party as such Grantor’s
        attorney‐in‐fact, with full authority in the place and stead of such Grantor and in the name of such Grantor, from time to time in Secured Party’s discretion, to take any action and to execute any instrument which Secured Party may deem necessary
        or advisable to accomplish the purposes of this Agreement, including (i) to modify, in its sole discretion, this Agreement without first obtaining such Grantor’s approval of or signature to such modification by amending Exhibits A, B and C, hereof, as
        appropriate, to include reference to any right, title or interest in any Copyrights, Patents or Trademarks acquired by such Grantor after the execution hereof or to delete any reference to any right, title or interest in any Copyrights, Patents or
        Trademarks in which such Grantor no longer has or claims any right, title or interest, (ii) to file, in its sole discretion, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the
        signature of Grantor where permitted by law, and (iii) after the occurrence and during the continuance of an Event of Default (as defined below), to transfer the Collateral into the name of Secured Party or a third party to the extent permitted
        under the Code.

     

      

    4.          Events of
            Default.  The occurrence of any of the following shall constitute an “Event of Default” under this Agreement:

     

      

    (a)          Subject to the provisions of Section 5.4 of the Exchange Agreement, Cibus
        commits a Payment Breach under the Exchange Agreement.

     

      

    (b)          Cibus materially breaches any warranty or agreement made by Cibus under
        the Exchange Agreement and, as to any breach that is capable of cure, Cibus fails to cure such breach within sixty (60) days of the sooner to occur of such Cibus’ of notice of such breach from Secured Party or the date on which such breach first
        becomes known to a responsible officer of Cibus.

     

      

    (c)          Any Grantor materially breaches any warranty or agreement made by such
        Grantor in this Agreement and, as to any breach that is capable of cure, such Grantor fails to cure such breach within sixty (60) days of the sooner to occur of such Grantor’s receipt of notice of such breach from Secured Party or the date on which
        such breach first becomes known to a responsible officer of such Grantor.

     

      

    (d)          Any Grantor shall (i) voluntarily terminate operations or apply for or
        consent to the appointment of, or the taking of possession by, a receiver, custodian, trustee or liquidator of the Grantor of all or a substantial part of the assets of the Grantor, (ii) admit in writing its inability to pay debts as the debts
        become due, (iii) make a general assignment for the benefit of its creditors, (iv) commence a voluntary case under the Federal Bankruptcy Code (as now or hereafter in effect), (v) file a petition seeking to take advantage of any other law relating
        to bankruptcy, insolvency, reorganization, winding-up, or composition or adjustment of debts, (vi) fail to controvert in a timely and appropriate manner, or acquiesce in writing to, any petition filed against it in an involuntary case under the
        Federal Bankruptcy Code or applicable state bankruptcy laws or (vii) take any corporate action for the purpose of effecting any of the foregoing; or

    
      5

      
        

    

    (e)          Without the Grantor’s application, approval or consent, a proceeding shall
        be commenced, in any court of competent jurisdiction, seeking in respect of the Grantor: the liquidation, reorganization, dissolution, winding-up, or composition or readjustment of debt, the appointment of a trustee, receiver, liquidator or the
        like relief in respect of the Grantor or all or any substantial part of the assets of the Grantor, or other like relief in respect of the Grantor` under any law relating to bankruptcy, insolvency, reorganization, winding-up, or composition or
        adjustment of debts; and, if the proceeding is being contested in good faith by the Grantor, the same shall continue undismissed, or unstayed and in effect for any period of 90 consecutive days, or an order for relief against the Grantor shall be
        entered in any case under applicable bankruptcy laws.

     

      

    5.          Remedies. 

        Upon the occurrence of any Event of Default, the Secured Party may at any time thereafter, at its option and, upon five (5) days written notice, exercise any or all of the following rights and remedies:

     

      

    (a)          collect, receive, appropriate, foreclose upon and/or sell or otherwise
        liquidate, and realize upon, the Collateral or any part thereof;

     

      

    (b)          exercise any or all of the rights and remedies granted to it under this
        Agreement or any other Transaction Document and take such other actions or proceedings as the Secured Party deems necessary or advisable to collect or enforce or to protect its interest in the Warrant Purchase Payments or the Collateral;

     

      

    (c)          enter, with or without process of law and without breach of the peace, any
        premises where the Collateral or the books and records of each applicable Grantor related thereto are or may be located, and without charge or liability to the Secured Party therefor seize and remove any tangible personal property evidencing the
        Collateral (and copies of the applicable Grantor's books and records in any way relating to the Collateral) from said premises and/or remain upon said premises and use the same (together with said books and records) for the purpose of collecting,
        preparing for sale and disposing of the Collateral;

     

      

    (d)          exercise any one or more of the rights and remedies accruing to the
        Secured Party under any applicable law, or as provided herein or in the Transaction Documents.  The Grantor recognizes that in the event it fails to perform, observe or discharge any of its obligations or liabilities under this Agreement, no remedy
        at law will provide adequate relief to the Secured Party, and each Grantor agrees that the Secured Party shall be entitled to temporary and permanent injunctive relief in any such case without the necessity of proving actual damages; and

    
      6

      
        

    

    (e)          exercise any and all of the rights and remedies of a secured party under
        the Code or comparable statute in the applicable jurisdiction, including, without limitation, the right to exercise all of the following rights and remedies:

    

    

    
      
        	

              	(i)	
                declare the entire right, title and interest of the Grantor in and to each of the Trademarks, together with all trademark rights and rights of protection to the same,
                    vested, in which event such rights, title and interest shall immediately vest, in the Secured Party;

              

      

    

    

    

    
      
        	

              	(ii)	
                declare the entire right, title and interest of the Grantor in and to each of the Patents and Copyrights vested, in which event such right, title and interest shall
                    immediately vest in the Secured Party;

              

      

    

    

    

    
      
        	

              	(iii)	
                to take and practice or use all or any portion of the Collateral;

              

      

    

    

    

    
      
        	

              	(iv)	
                to sell, license, or otherwise dispose of any or all of the Collateral, including the goodwill of the Grantor’s or Cibus’ business symbolized by the Trademarks and the
                    right to carry on the business and use the assets of the Grantor and Cibus in connection with which the Trademarks have been used (excluding, in each case, the Nucelis business with respect to the Grantor and Cibus);

              

      

    

    

    

    
      
        	

              	(v)	
                to apply the proceeds of the Collateral towards (but not necessarily in complete satisfaction of) the obligations of Cibus under the Exchange Agreement; and/or

              

      

    

    

    

    
      
        	

              	(vi)	
                to direct the Grantor to refrain from practicing or using the Collateral in any manner whatsoever other than in connection with the Grantor’s or Cibus’ Nucelis business,
                    directly or indirectly, and, if requested by the Secured Party, change the Grantor’s corporate name to eliminate therefrom any use of any Trademark, as applicable, and execute such other and further documents that the Secured Party may
                    request to further confirm this and to transfer ownership of the Collateral and any associated goodwill to the Secured Party.

              

      

    

    
      7

      
        

    

    Any sale or other disposition of the Collateral may be at public or private sale upon such terms and in such manner as the Secured Party
        deems advisable, having due regard to compliance with any statute or regulation which might affect, limit, or apply to the Secured Party's disposition of the Collateral.  Unless otherwise permitted by law (in which event the Secured Party shall
        provide the Grantor with such notice as may be practicable under the circumstances), the Secured Party shall give the Grantor at least the greater of the minimum notice required by law or seven (7) days prior written notice of the date, time, and
        place of any proposed public sale of, and of the date after which any private sale or other disposition, of the Collateral, or any portion thereof, is to be made.

    

    

    Such options may be exercised individually, sequentially or in concert, all such remedies being cumulative, the exercise of one not being deemed a waiver of
        any other or a cure of any Event of Default.  An Event of Default shall not be deemed to be in existence or to be continuing for any purpose of this Agreement if the Secured Party pursuant to this Agreement shall have waived such event in writing
        or stated in writing that the same has been cured to its reasonable satisfaction, but no such waiver shall extend to or affect any subsequent Event of Default or impair any rights of the Secured Party upon the occurrence thereof.

    

    

    Additionally, after the occurrence of an Event of Default, the Secured Party shall have the right, but not the duty, to intervene or otherwise participate in
        any legal or equitable proceeding which, in the Secured Party’s sole judgment, affects the Collateral or any of the rights created or secured by this Agreement.

    

    

    6.          Liability
            for Collateral.  So long as the Secured Party employs reasonable practices regarding the safekeeping of the Collateral in the possession or under the control of the Secured Party, (a) the Secured Party shall not be liable or
        responsible for: (i) the safekeeping of the Collateral, (ii) any loss or damage to the Collateral, (iii) any diminution in value of the Collateral or (iv) any act or default if any carrier, warehouseman, bailee or other Person and (b) the Grantors
        shall bear all risk of loss, damage or destruction of the Collateral.

     

      

    7.          No
            Waiver, Remedies Cumulative.  The Secured Party’s failure, at any time or times, to require strict performance by any of the Grantors of any provision of this Agreement shall not waive, affect or diminish any right of the Secured
        Party thereafter to demand strict performance and compliance herewith.  No waiver of any of Secured Party’s rights or any of the Grantors’ obligations hereunder shall be effective unless signed by the Secured Party and then is only effective for
        the specific instance and purpose for which it is given.  The Secured Party’s rights and remedies under this Agreement are cumulative.  The Secured Party has all rights and remedies provided under the Code and any applicable law, by law, or in
        equity.  The Secured Party’s delay in exercising any remedy is not a waiver, election or acquiescence.

     

      

    8.          Amendments. 

        This Agreement may be amended only by a written instrument signed by Cibus and Secured Party, except for amendments permitted under Section 3 hereof to be made by Secured Party alone.  Any amendment to this Agreement made in accordance with the
        foregoing shall be binding upon all parties to this Agreement.

     

      

    9.          Governing
            Law.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of
        any other jurisdiction.

    
      8

      
        

    

    10.        Counterparts. 

        This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.  Signatures delivered by facsimile or electronic transmission shall have the same
        effect as original signatures.

    

    

    

    

    [Signature Pages Follow]

    

    

    
      9

      
        

    

    IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

     

      

    	 	
            GRANTORS:

          
	
            Address of Grantor:

          	
            Cibus Global, Ltd.

          
	
            See Schedule A

          	
            By:

          	/s/ Peter Beetham
	 	Name:	Peter Beetham, Ph.D.
	 	Title:	President
                & Chief Executive Officer
	 	 	 
	
            Address of Grantor:

          	
            Cibus International GP, Ltd.

          
	
            See Schedule A

          	
            By:          

            

          	 /s/ Gerard C. Pilon   

          
	 	Name:	 Gerard C. Pilon, Ph.D. 

          
	 	Title:	 Corporate Representative 

          
	 	 	 
	
            Address of Grantor:

          	
            Cibus International, L.P.

          
	
            See Schedule A

          	
            By:     

            

          	 /s/ Gerard C. Pilon   

          
	 	Name:	 Gerard C. Pilon, Ph.D.  

          
	 	Title:	 Corporate Representative
	 	 	 
	
            Address of Grantor:

          	
            Cibus Netherlands Partners, Ltd.

          
	
            See Schedule A

          	
            By:  

          	  /s/ Peter
              Beetham      

          
	 	Name:	 Peter Beetham, Ph.D.
	 	Title:	 President
                & Chief Executive Officer
	 	 	 
	
            Address of Grantor:

          	
            Cibus Netherlands Holding Cooperatif U.A.

          
	
            See Schedule A

          	
            By:         

            

          	 /s/ Gerard C. Pilon 

          
	 	Name:	 Gerard C. Pilon, Ph.D
	 	Title:	 Director
	 	 	 

    

    [SIGNATURE PAGE TO IP SECURITY AGREEMENT]

    
      
        

    

    	
            Address of Grantor:

          	
            Incima Europe B.V.

          
	
            See Schedule A

          	
            By:   

            

          	 /s/ Gerard C. Pilon  

          
	 	Name:	 Gerard C. Pilon, Ph.D.   

          
	 	Title:	 Director  

          
	 	 	 
	
            Address of Grantor:

          	
            Cibus Europe Ltd.

          
	
            See Schedule A

          	
            By:         

            

          	 /s/ Gerard C. Pilon 

          
	 	Name:	 Gerard C. Pilon, Ph.D.  

          
	 	Title:	 Director 

          
	 	 	 
	
            Address of Grantor:

          	
            Cibus US LLC

          
	
            See Schedule A

          	
            By:  

          	  /s/ Peter
              Beetham    

          
	 	Name:	 Peter Beetham, Ph.D.    

          
	 	Title:	 President
                & Chief Executive Officer
	 	 	 
	
            Address of Grantor:

          	
            Cibus Canada Inc.

          
	
            See Schedule A

          	
            By: 

              

          	 /s/ Peter Beetham
	 	Name:	 Peter Beetham, Ph.D.    

          
	 	Title:	 President
                & Chief Executive Officer
	 	 	 
	
            Address of Grantor:

          	
            Incima B.V.

          
	
            See Schedule A

          	
            By: 

          	 /s/ Greg Gocal
	 	Name:	 Greg Gocal, Ph.D.  

          
	 	Title:	 Senior Vice
                President Research and Development
	 	 	 

    

    [SIGNATURE PAGE TO IP SECURITY AGREEMENT]

    
      
        

    

    	
            Address of Grantor:

          	
            Incima IPCO B.V.

          
	
            See Schedule A

          	
            By: 

          	 /s/ Greg Gocal    

          
	 	Name:	 Greg Gocal, Ph.D. 

          
	 	Title:	 Senior Vice
                President Research and Development
	 	 	 
	
            Address of Grantor:

          	
            Incima US LLC

          
	
            See Schedule A

          	
            By: 

          	 /s/ Greg Gocal    

          
	 	Name:	 Greg Gocal, Ph.D.  

          
	 	Title:	 Senior Vice
                President Research and Development
	 	 	 
	 	 	 

    

    

    

    

    	 	
            SECURED PARTY:

          
	
            Address of Secured Party:

          	
            RORY RIGGS

          
	c/o Balfour, LLC	/s/ Rory Riggs

          
	
            110 East 59th St.

            33rd Floor

            New York, NY 10022 

            

          	
              

            

          	 
	 	 	 
	 	 	 

    
      [SIGNATURE PAGE TO IP SECURITY AGREEMENT]

    

    
      
        

    

    

    

    SCHEDULE A

    

    

    GRANTORS

    

    

    	
            Name of Grantor

          	
            Jurisdiction or Organization

          	
            Address 

            

          
	
            Cibus Global, Ltd.

          	
            British Virgin Islands

          	
            Nemours Chambers

            PO Box 3170

            Road Town, Tortola, VG 1110

             

          
	
            Cibus International GP, Ltd.

          	
            British Virgin Islands

          	
            Nemours Chambers

            PO Box 3170

            Road Town, Tortola, VG 1110

             

          
	
            Cibus International, L.P.

          	
            British Virgin Islands

          	
            Nemours Chambers

            PO Box 3170

            Road Town, Tortola, VG 1110

             

          
	
            Cibus Netherland Partners, Ltd.

             

          	
            British Virgin Islands

          	
            Nemours Chambers

            PO Box 3170

            Road Town, Tortola, VG 1110

             

          
	
            Cibus Netherlands Holding Cooperatif U.A.

          	
            The Netherlands

          	
            Goessestraatweg 19

            4421 AD Kapelle

             

          
	
            Cibus Europe B.V.

          	
            The Netherlands

          	
            Goessestraatweg 19

            4421 AD Kapelle

             

          
	
            Incima Netherlands Holding Cooperatif U.A.

          	
            The Netherlands

          	
            Goessestraatweg 19

            4421 AD Kapelle

             

          
	
            Incima Europe B.V.

          	
            The Netherlands

          	
            Goessestraatweg 19

            4421 AD Kapelle

             

          
	
            Cibus Europe Ltd.

          	
            The United Kingdom

          	
            Salt Quay House

            4 North East Quay

            Sutton Harbor

            Plymouth PL4 0BN

             

          
	
            Cibus US LLC

          	
            Delaware, USA

          	
            6455 Nancy Ridge Drive,

                Suite 100

                San Diego, CA 92121

             

          
	
            Cibus Canada Inc.

          	
            Canada

          	
            1700-360 Main Street

            Winnipeg, Manitoba R3C 3Z3

             

          
	
            Incima B.V.

          	
            Curacao

          	
            Kaya W.F.G. (Jombi)

            Mensing 14, 2nd Floor

            Willemstad

             

          
	
            Incima IPCO B.V.

          	
            Curacao

          	
            Kaya W.F.G. (Jombi)

            Mensing 14, 2nd Floor

            Willemstad

             

          
	
            Incima US LLC

          	
            Delaware, USA

          	
            6455 Nancy Ridge Drive,

                Suite 100

                San Diego, CA 92121

             

          

    

    

    
      
        

    

    EXHIBIT A

    

    

    Copyrights

    

    

    None.

    

    

    	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

    

    
      
        

    

    EXHIBIT B

    

    

    Patents

     

      

    
      	
              Country Code

            	
              Application No. / Patent No.

            	
              Status

            	
              Nominal Expiration (by family)

            
	
              US

            	
              09/129,298

              7,094,606

            	
              Issued Patent

            	
              8/5/2018

            
	
              US

            	
              14/476,674

            	
              Pending

            	
              8/5/2018

            
	
              AU

            	
              502929

            	
              Issued Patent

            	
              8/5/2018

            
	
              CN

            	
              ZL98809867.9

            	
              Issued Patent

            	
              8/5/2018

            
	
              US

            	
              09/129,036

              8,106,259

            	
              Issued Patent

            	
              10/6/2020

            
	
              US

            	
              09/429,291

              6,573,046

            	
              Issued Patent

            	
              5/12/2018

            
	
              US

            	
              09/384,960

              6,271,360

            	
              Issued Patent

            	
              8/27/2029

            
	
              US

            	
              09/645,889

              6,479,292

            	
              Issued Patent

            	
              8/27/2029

            
	
              US

            	
              10/292,856

              7,060,500

            	
              Issued Patent

            	
              8/27/2029

            
	
              ZA

            	
              2002/1228

            	
              Issued Patent

            	
              8/27/2029

            
	
              NZ

            	
              517942

            	
              Issued Patent

            	
              8/27/2029

            
	
              JP

            	
              2001-520151

            	
              Allowed

            	
              8/27/2029

            
	
              EP

            	
              00959442.5

            	
              Issued Patent

            	
              8/27/2029

            
	
              CN

            	
              00814996.8

            	
              Issued Patent

            	
              8/27/2029

            
	
              CA

            	
              2,382,120

            	
              Issued Patent

            	
              8/27/2029

            
	
              AU

            	
              7076700*

            	
              Issued Patent

            	
              8/27/2029

            
	
              AU

            	
              2004205139

            	
              Issued Patent

            	
              8/27/2029

            
	
              EP

            	
              10008602.4

            	
              Allowed

            	
              8/27/2029

            
	
              EP

            	
              10183960.3

            	
              Allowed

            	
              8/27/2029

            
	
              US

            	
              09/429,292

              6,211,351

            	
              Issued Patent

            	
              5/12/2018

            
	
              US

            	
              09/825,124

              6,586,184

            	
              Issued Patent

            	
              5/12/2018

            

      
        
          

      

      

      

      	
              PCT

            	
              PCT/US2014/029566

            	
              Pending

            	
              3/14/ 2034

            
	
              PCT

            	
              PCT/US2014/029621

            	
              Pending

            	
              3/14/ 2034

            
	
              US

            	
              61/95 3,333

            	
              Pending / Confidential

            	
              3/14/ 2015

            
	
              US

            	
              62/051,579

            	
              Pending / Confidential

            	
              9/17/2015

            
	
              US

            	
              62/075,811

            	
              Pending / Confidential

            	
              11/5/2015

            
	
              US

            	
              62/075,816 c

            	
              Pending / Confidential

            	
              11/5/2015

            
	
              US

            	
              62/09 3,287

            	
              Pending / Confidential

            	
              12/17/2015

            
	
              US

            	
              12/306,477 8,029,579

            	
              Issued Patent

            	
              6/27/2027

            
	
              AU

            	
              2007265434

            	
              Allowed

            	
              6/27/2027

            
	
              BY

            	
              a20090110

            	
              Pending

            	
              6/27/2027

            
	
              CA

            	
              2656557

            	
              Pending

            	
              6/27/2027

            
	
              IN

            	
              392/KOLNP/2009

            	
              Pending

            	
              6/27/2027

            
	
              NZ

            	
              574390

            	
              Issued Patent

            	
              6/27/2027

            
	
              RU

            	
              2009101866 2483057

            	
              Issued Patent

            	
              6/27/2027

            
	
              UA

            	
              2009 00631

            	
              Issued Patent

            	
              6/27/2027

            
	
              EP

            	
              07809993.4

            	
              Pending

            	
              6/27/2027

            
	
              HK

            	
              09109108.1

            	
              Pending

            	
              6/27/2027

            
	
              US

            	
              13/227,437 8,361,173

            	
              Issued Patent

            	
              6/27/2027

            
	
              AU

            	
              2012244362

            	
              Pending

            	
              6/27/2027

            
	
              US

            	
              13/752,330

            	
              Pending

            	
              6/27/2027

            
	
              UA

            	
              a 2014 07835

            	
              Pending

            	
              6/27/2027

            
	
              EP

            	
              13178514.9

            	
              Pending

            	
              6/27/2027

            
	
              NZ

            	
              612190

            	
              Pending

            	
              6/27/2027

            
	
              UA

            	
              Awaiting

            	
              Pending

            	
              6/27/2027

            
	
              JP

            	
              2014-208612

            	
              Pending

            	
              6/27/2027

            
	
              US

            	
              12/81 0,142

            	
              Pending

            	
              12/27 /2027

            
	
              EP

            	
              7868087.3

            	
              Pending

            	
              12/27/2027

            
	
              AU

            	
              2007363151

            	
              Pending

            	
              12/27/2027

            
	
              CA

            	
              2710767

            	
              Pending

            	
              12/27/2027

            
	
              IN

            	
              4622/DELNP/2010

            	
              Pending

            	
              12/27/2027

            

      
        
          

      

      

      

      	
              NZ

            	
              586965

            	
              Issued Patent

            	
              12/27/2027

            
	
              EA

            	
              201070649

            	
              Pending

            	
              12/27/2027

            
	
              UA

            	
              a 2010 07990

            	
              Pending

            	
              12/27/2027

            
	
              HK

            	
              11102423

            	
              Pending

            	
              12/27/2027

            
	
              NZ

            	
              621327

            	
              Pending

            	
              12/27/2027

            
	
              JP

            	
              2014-208524

            	
              Pending

            	
              12/27/2027

            
	
              US

            	
              12/24 5,610

            	
              Pending

            	
              10/3/2028

            
	
              US

            	
              13/407,676

            	
              Pending

            	
              10/3/2028

            
	
              AU

            	
              2008308530

            	
              Pending

            	
              10/3/2028

            
	
              CA

            	
              2701624

            	
              Pending

            	
              10/3/2028

            
	
              EP

            	
              08836084.7

            	
              Pending

            	
              10/3/2028

            
	
              IN

            	
              3168/DELNP/2010

            	
              Pending

            	
              10/3/2028

            
	
              JP

            	
              2010-528175

            	
              Pending

            	
              10/3/2028

            
	
              UA

            	
              103887

              a 2010 05275

            	
              Issued Patent

            	
              10/3/2028

            
	
              CL

            	
              2010-344

            	
              Pending

            	
              10/3/2028

            
	
              CN

            	
              200880119084.3

            	
              Pending

            	
              10/3/2028

            
	
              BR

            	
              PI0818295-7

            	
              Pending

            	
              10/3/2028

            
	
              EA

            	
              201070430

            	
              Pending

            	
              10/3/2028

            
	
              CN

            	
              201110133906.7

            	
              Pending

            	
              10/3/2028

            
	
              HK

            	
              11104608.3

            	
              Pending

            	
              10/3/2028

            
	
              NZ

            	
              606701

            	
              Pending

            	
              10/3/2028

            
	
              EP

            	
              13175389.9

            	
              Pending

            	
              10/3/2028

            
	
              EP

            	
              131753931

            	
              Pending

            	
              10/3/2028

            
	
              UA

            	
              a 2013 09872

            	
              Pending

            	
              10/3/2028

            
	
              US

            	
              09/685,403 6,870,075

            	
              Issued Patent

            	
              10/10/2020

            
	
              US

            	
              11/941,666

            	
              Pending

            	
              10/10/2020

            
	
              EP

            	
              00970716.7

            	
              Issued Patent

            	
              10/10/2020

            
	
              EP

            	
              09172695.0

            	
              Issued Patent

            	
              10/10/2020

            
	
              EP

            	
              10183984.3

            	
              Pending

            	
              10/10/2020

            
	
              EP

            	
              12197905.8

            	
              Pending

            	
              10/10/2020

            
	
              AU

            	
              8005200*

            	
              Issued Patent

            	
              10/10/2020

            
	
              JP

            	
              2014-243991

            	
              Pending

            	
              10/10/2020

            
	
              UA

            	
              20081 0303

            	
              Issued Patent

            	
              1/10/2027

            

      
        
          

      

      

      

      	
              RU

            	
              2441366 2008133046

            	
              Issued Patent

            	
              1/10/2027

            
	
              NZ

            	
              570009

            	
              Issued Patent

            	
              1/10/2027

            
	
              JP

            	
              2008-550371

            	
              Pending

            	
              1/10/2027

            
	
              IN

            	
              3599/CHENP/2008

            	
              Pending

            	
              1/10/2027

            
	
              CA

            	
              2636771

            	
              Pending

            	
              1/10/2027

            
	
              BY

            	
              a20081068

            	
              Pending

            	
              1/10/2027

            
	
              AU

            	
              2007207813

            	
              Issued Patent

            	
              1/10/2027

            
	
              US

            	
              8,268,622 12/160725

            	
              Issued Patent

            	
              1/10/2027

            
	
              NZ

            	
              597682

            	
              Issued Patent

            	
              1/10/2027

            
	
              EP

            	
              12152491.2

            	
              Allowed

            	
              1/10/2027

            
	
              EP

            	
              12152493.8

            	
              Allowed

            	
              1/10/2027

            
	
              US

            	
              13/621,662

            	
              Pending

            	
              1/10/2027

            
	
              NZ

            	
              613267

            	
              Pending

            	
              1/10/2027

            
	
              PC

            	
              T PCT/US201 4/029434

            	
              Pending

            	
              3/14/ 2034

            
	
              US

            	
              62/051,876

            	
              Pending / Confidential

            	
              9/17/2015

            
	
              U S

            	
              13/93 5,532

            	
              Pending

            	
              8/2/2 031

            
	
              AU

            	
              201125830

            	
              Pending

            	
              8/2/2031

            
	
              BR

            	
              112013002543.3

            	
              Pending

            	
              8/2/2031

            
	
              CA

            	
              2,807,035

            	
              Pending

            	
              8/2/2031

            
	
              CL

            	
              00341-2013

            	
              Pending

            	
              8/2/2031

            
	
              CN

            	
              201180048304X

            	
              Pending

            	
              8/2/2031

            
	
              EA

            	
              201390034

            	
              Pending

            	
              8/2/2031

            
	
              EP

            	
              11815228.9

            	
              Pending

            	
              8/2/2031

            
	
              IL

            	
              224535

            	
              Pending

            	
              8/2/2031

            
	
              IN

            	
              188/MUMNP/2013

            	
              Pending

            	
              8/2/2031

            
	
              JP

            	
              2013523291

            	
              Pending

            	
              8/2/2031

            
	
              KR

            	
              10-2013-7005453

            	
              Pending

            	
              8/2/2031

            
	
              MX

            	
              MXa2013001299

            	
              Pending

            	
              8/2/2031

            
	
              NZ

            	
              607627

            	
              Pending

            	
              8/2/2031

            
	
              UA

            	
              a201302555

            	
              Pending

            	
              8/2/2031

            
	
              ZA

            	
              2013/01067

            	
              Pending

            	
              8/2/2031

            
	
              U S

            	
              62/09 9,330 Pending / Confidential

            	
              1/2/2 016

            	 
	
              U S

            	
              62/10 2,824

            	
              Pending / Confidential

            	
              1/13/ 2016

            

      
        
          

      

      

      

      	
              US

            	
              62/10 2,827

            	
              Pending / Confidential

            	
              1/13/ 2016

            
	
              US

            	
              62/08 0,907

            	
              Pending / Confidential

            	
              11/17 /2015

            
	
              US

            	
              62/10 2,010

            	
              Pending / Confidential

            	
              1/10/ 2016

            
	
              US

            	
              62/05 1,876

            	
              Pending / Confidential

            	
              1/10/ 2016

            

      

      

    

    
      
        

    

    

    

    EXHIBIT C

    

    

    Trademarks

    

    

    	
            Trademark

          	
            Country Code

          	
            Application No. /

                Patent No.

          	
            Status

          
	 	 	 	 
	
            SU Canola (Stylized and/or with design)

          	
            US

          	
            86/447,539

          	
            Pending

          
	
            SU Canola (Standard Characters)

          	
            US

          	
            86/447,537

          	
            Pending

          
	
            Cibus (Stylized and/or with design)

          	
            US

          	
            86/447,534

          	
            Pending

          
	
            Cibus (Standard Characters)

          	
            US

          	
            86/447,529

          	
            Pending

          
	
            RTDS

          	
            US

          	
            Not yet filed

          	
            Application Filing in Progress

          
	
            Nucelis

          	
            US

          	
            Not yet filed

          	
            Application Filing in ProgressExhibit

      10.20

      

   

      

  CIBUS GLOBAL, LTD.

  2016 RESTRICTED SHARES PLAN.

  

  

  Cibus Glohal, Ltd., a company incorporated under the laws of the British Virgin Islands (the “Company”), pursuant to resolutions adopted by the Board of Directors of the Company (the

      “Board”) dated March 14, 2016, does hereby adopt the following 2016 Restricted
        Shares Plan (the “Restricted Shares Plan”), effective as of June 1, 2016 (the “Effective Date”):

  

  

  (1)          The Board

        shall be, and hereby is, authorized to issue non-voting Common Shares pursuant to this Restricted Shares Plan to one or more additional recipients who are officers, directors, employees, executives, consultants, advisors or
        other similar service providers of the Company or any of its subsidiaries, upon such terms and conditions as shall be approved by the
        Board. Initially, all grants of
        shares under the Restricted Shares Plan

      shall be for Common Shares
        (non-voting); provided, however, that the Board may at any time and in its sole discretion convert all or any portion of the Common Shares (non-voting) granted under the Restricted Shares Plan into Voting Common Shares.

  

  

  (2)          The Board,

        as the administrator of the Restricted Share Plan, shall have flexibility

        in establishing the terms and conditions of the shares to be granted pursuant to the Restricted Share Plan, including with respect to the vesting schedule, if any, governing any such grants.

  

  

  (3)          The Board may, in its discretion, issue

        shares pursuant to the Restricted Share Plan which are fully-vested on the date of grant.

  

  

  (4)          The following additional terms and conditions shall apply to the Restricted Shares Plan and any issuances of restricted Common Shares pursuant thereto:

  

  

  (a)          The total number of restricted Common Shares issued under the Restricted Shares Plan shall initially equal to 22,336,005 Common Shares; provided, however, that the total number of Common Shares available for issuance under the Restricted Share Plan shall automatically increase in connection with any future equity financing transactions undertaken by the Company such that the total number of Common Shares which may be issued under the Restricted Share Plan shall represent 15% of the Company’s outstanding equity on a fully-diluted basis;

  

  

  (b)          The grants set forth on Schedule A previously made by the Company pursuant to the 2009 Restricted Share Plan shall apply against the total number of Common Shares available for issuance pursuant to the Restricted Share Plan. All other grants made pursuant to the Company’s 2009 Restricted Share Plan will

      not apply against the total number of Common Shares available for issuance pursuant
      to the Restricted Share Plan;

  

  

  (c)          Any shares (i) issued pursuant to the Restricted Share Plan or (ii) issued pursuant to the Company’s 2009 Restricted

      Share Plan and rolled into this Restricted Share Plan pursuant to Section 4(b), which are subsequently reacquired by the Company shall immediately become available for issuance pursuant to the Restricted Share Plan;

  

  

  (d)          The Company shall at all times reserve and keep available sufficient Common Shares to satisfy the requirements of the Restricted Share Plan;

  

  

  
    
      

  

  (e)          In the case of issuances of restricted Common Shares to consultants or advisors of the Company, no award may be granted unless such
        consultant or advisor (a) is a natural
      person, (b) provides bona fide services to the Company and (c) such services are not in connection with the sale of the Company’ s Common Shares in a capital-raising transaction;

  

  

  (f)          In connection with each grant of Common Shares pursuant to the Restricted Shares Plan, the recipient shall enter into a Restricted

        Shares Purchase Agreement with the Company, which agreement shall set forth
        the terms and conditions associated with such Restricted Shares. The provisions of the various Restricted Shares Purchase Agreements entered into under this Restricted Share Plan need not be identical;

  

  

  (g)          Any Common Shares awarded or sold under this Restricted Share Plan shall be subject to such special forfeiture conditions, rights

      of repurchase, rights of first refusal and other transfer restrictions as the Board may determine. Such
      restrictions shall be set forth in the applicable Restricted Shares Purchase Agreement and shall apply in addition to any restrictions that may apply to holders of shares generally, including those set f01th in the Company’s Amended and Restated Memorandum and
      Articles of Association;

  

  

  (h)          No participant in the Restricted Shares Plan shall be permitted to
        transfer, assign, encumber or otherwise convey all or any portion of such participant’s rights to acquire securities pursuant to the Restricted Shares Plan, except by will, the laws of descent and distribution,

      or as pe1mitted by Rule 701 of the Securities Act of 1933, as
        amended (17 C.F.R. 230.701);

  

  

  (i)          The Restricted

        Shares Plan shall have a term of ten (10) years

        from the Effective Date  and no
        additional shares of Common Shares shall be issued pursuant to the Restricted Shares Plan following the expiration of such ten year term; and

  

  

  (j)          All issuances of securities pursuant to the Restricted Shares Plan shall comply with the provisions of Rule 701 of the Securities Act of 1933, as amended (17 C.F.R. 230.70l), and all securities laws of the British Virgin Islands, each if applicable.

  

  

  (5)          This Restricted Shares Plan may be amended by the Board at any time and from

      time to time.

  

  

  (6)          All capitalized terms used herein and not

      otherwise defined shall have the meaning ascribed to them in the Company’s Amended and Restated Memorandum and Articles of Association.

  

  

  * * *

  
    
      

  

  IN WITNESS WHEREOF,
        the Company has executed this Restricted Shares Plan effective as of the Effective Date.

  

  

  

  

  	 	
          Cibus Global, Ltd.

        
	 	 	 
	 	
          By:

        	/s/ Peter Beetham

        
	 	
          Name: Peter Beetham

        
	 	
          Title: CEO

        

  

  

  
    
      

  

  Common Shares Cibus Global Ltd

  April 30, 2016

  Schedule A

  

  

  

  

  	 	
          Included in 

          incentive 

          pool

        	 
	 	 	 
	
          Total

        	 7,767,772	 	 
	
          Rory Riggs

        	
          184,807

        	
          Karin Braemer

        	
          6,422

        
	
          Jean-Pierre Lehmann

        	
          62,261

        	
          Kimberly Butler De Rose

        	
          6,672

        
	
          Keith A Walker

        	
          486,982

        	
          Patrick Calubaquib

        	
          5,422

        
	
          David Voss

        	
          209,274

        	
          Tara Denholm

        	
          5,422

        
	
          Eugene Linden

        	
          163,674

        	
          Timothy Fraley

        	
          8,331

        
	
          Peter Beetham

        	
          1,167,025

        	
          Brian Freitas

        	
          3,422

        
	
          Mark Knuth

        	
          115,128

        	
          Daniel Galindo

        	
          5,422

        
	
          Jennifer Barker

        	
          138,522

        	
          Amanda Habel

        	
          8,051

        
	
          Greg Gocal

        	
          941,434

        	
          Jameson Hall

        	
          7,122

        
	
          Christian Schopke

        	
          237,651

        	
          Long Huynh

        	
          5,422

        
	
          Rosa Segami (Carcamo)

        	
          30,722

        	
          Sarah Knuth

        	
          5,422

        
	
          Andrew Walker

        	
          42,297

        	
          Tomas Lagunas

        	
          5,722

        
	
          Aura Gonzalez de Schopke

        	
          27,022

        	
          Edgardo Leon

        	
          7,620

        
	
          James Radtke

        	
          293,000

        	
          Antonio Licup

        	
          4,582

        
	
          Amber Hunter (Bowers}

        	
          11,022

        	
          Tracey Lincoln

        	
          14,824

        
	
          Satyendra Rajguru

        	
          45,722

        	
          Yohannes Mihirit

        	
          8,916

        
	
          Noel Fong

        	
          24,571

        	
          Gregory Newkirk

        	
          6,751

        
	
          Mark Finn

        	
          91,574

        	
          Lynn Nguyen

        	
          7,672

        
	
          Cathy Hays

        	
          60,922

        	
          Douglas Potter

        	
          4,883

        
	
          Kim Hanson

        	
          31,222

        	
          Anna Quiroz

        	
          6,422

        
	
          Nathalie Kind

        	
          30,222

        	
          Claudia Quiroz

        	
          6,422

        
	
          Amber Perry

        	
          17,685

        	
          Erich Rosenberger

        	
          16,836

        
	
          Richard Ju

        	
          8,250

        	
          Michael Rozas

        	
          3,620

        
	
          Gerard Pilon

        	
          306,500

        	
          Reema Saleh

        	
          6,394

        
	
          Liliana Gavino

        	
          10,322

        	
          Derek Sanford

        	
          8,260

        
	
          Supriya Huilgol

        	
          12,322

        	
          Keith Sebourn

        	
          7,620

        
	
          Karen Troeber

        	
          37,022

        	
          Dorinda Moellering

        	
          31,422

        
	
          Alain Pompidou

        	
          68,839

        	
          Riannon Mashore

        	
          6,422

        
	
          Uvini Gunawardena

        	
          68,272

        	
          Dillan Stengel

        	
          7,142

        
	
          Ryan Miller

        	
          13,916

        	
          Chun Ning Elijah Tang

        	
          5,422

        
	
          Stephanie Kearney

        	
          8,222

        	
          Laszlo Treiber

        	
          74,672

        
	
          Rosa Cheuk Kim

        	
          112,972

        	
          Hector Vidal

        	
          4,582

        
	
          Carlo Broos

        	
          134,522

        	
          Hassan Waheed

        	
          1,722

        
	
          Tony Moran

        	
          198,100

        	
          Zachary Warburg

        	
          6,422

        
	
          Gerhard Prante

        	
          68,839

        	
          Melody Woodward

        	
          8,716

        
	
          Christopher Richards

        	
          145,839

        	
          Bastiaan Bargmann

        	
          6,700

        
	
          David Songstad

        	
          31,722

        	
          Mathew Pett

        	
          7,380

        
	
          Clint Dotterer

        	
          51,372

        	
          Olga Batalov

        	
          5,775

        
	
          Jerry Mozoruk

        	
          52,116

        	
          LemLem Catalano

        	
          6,860

        
	
          Javier Narvaez-Vasquez

        	
          61,416

        	
          Taheer Dattaray

        	
          4,700

        
	
          Emma Short

        	
          8,422

        	
          Felipe Strefling

        	
          4,380

        
	
          David Weiser

        	
          9,151

        	
          Jina Heisman

        	
          3,700

        
	
          Noel Sauer

        	
          106,116

        	
          Oscar Suarez

        	
          4,540

        
	
          Dolendro Singh

        	
          13,422

        	
          Wochok Revocable Trust

        	
          145,839

        
	
          Steven Sanders

        	
          90,779

        	
          Scot Anderson

        	
          5,000

        
	
          Harry Glorikan

        	
          145,839

        	
          Mark Lu

        	
          125,906

        
	
          Sean O Connor

        	
          489,200

        	
          Hendrik Meerman

        	
          40,000

        
	
          Doug Taylor

        	
          76,549

        	
          Garret Groves

        	
          5,000

        
	
          Janine Taylor

        	
          130,000

        	
          Cheng Fang

        	
          2,860

        
	
          Tim Krupa

        	
          77,400

        	
          Michael Gehris

        	
          2,700

        
	
          StacyLeppert

        	
          95,700

        	
          Shane Maslanka

        	
          1,380

        
	
          Kim Anderson

        	
          17,422

        	
          Amirali Sattarzadeh Mohammadi

        	
          1,554

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00291-of-00352.parquet"}]]